Status and phase
Conditions
Treatments
About
phase II clinical trial to evaluate node-sparing short-course radiation combined with total neoadjuvant CAPOX and Sintilimab for MSS locally advanced rectal cancers.
Full description
This is an open-label, prospective, single-center phase II clinical trial to evaluate node-sparing short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with total neoadjuvant CAPOX and PD-1 Inhibitor (Sintilimab) for patients with MSS locally advanced of middle and low rectal cancer. A total of 47 patients will be enrolled in this trial. The primary endpoint is the complete response(CR) rate, which includes cCR and pCR. The organ preservation rate, tumor regression grade, 3-year DFS, 3-year OS, and adverse effects will also be analyzed.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other conditions that investigators consider not suitable for this study.
Primary purpose
Allocation
Interventional model
Masking
37 participants in 1 patient group
Loading...
Central trial contact
cheng cai, master; jinlin du, master
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal